Outcomes Reporting in Specialty Highlights SPT Week in Review
SPT StaffPublish Date: Friday, March 16, 2018
5. Sanofi, Regeneron to Reduce Costs for PCSK9 Inhibitor for Value-Based Contracts
Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!
Payers may achieve an additional discount for alirocumab (Praluent) if they agree to value-based contracts. Read more.
4. Fish Consumption Linked to Lower Multiple Sclerosis Risk
4. Fish Consumption Linked to Lower Multiple Sclerosis Risk
Intake of fish high in omega-3 fatty acids could help reduce the risk of developing multiple sclerosis or clinically isolated syndrome. Read more.
3. Drug Costs May Not Solely Drive Increasing US Health Care Spending
3. Drug Costs May Not Solely Drive Increasing US Health Care Spending
Administrative costs and surgical procedures may contribute significantly to overspending on health care in the United States. Read more.
2. Top 3 Most Common Cognitive Effects of Multiple Sclerosis
2. Top 3 Most Common Cognitive Effects of Multiple Sclerosis
Patients with multiple sclerosis may be at a higher risk of developing mental health conditions. Read more.
1. Outcomes Reporting: A Specialty Pharmacy Core Competency
Collecting data that show the most efficient and effective ways to clinically manage patients is becoming more important than ever in specialty pharmacy. Read more.
1. Outcomes Reporting: A Specialty Pharmacy Core Competency
Collecting data that show the most efficient and effective ways to clinically manage patients is becoming more important than ever in specialty pharmacy. Read more.
Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.
Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.
Click here to follow us on Facebook.
Click here to follow us on Twitter.
Click here to join our LinkedIn group.
Most Popular
Related Articles
New analysis from a phase 3 trial reports that oral, once-daily siponimod (BAF312) consistently reduced disability progression in patients with secondary progressive multiple sclerosis.
John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses the data customers should be asking for from a specialty pharmacy.
Top news of the week from Specialty Pharmacy Times.